Search Results

RemeGen Co., Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a commercial-stage biotechnology company, showcased its innovation in the field of global cancer treatment at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) held in Chicago from May 31-June 4, 2024.

RemeGen Co., Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-label, multi-center Phase I/II study evaluating RC88 in patients with MSLN-expressing advanced solid tumors on June 3, at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) held in Chicago from May 31-June 4, 2024.

RemeGen Co. Ltd., a commercial-stage biotechnology company, obtained Fast Track Designation by the United States Food and Drug Administration recently for its innovative BLyS/APRIL dual-target fusion protein drug, Telitacicept, independently developed by RemeGen for the treatment of patients with primary Sjögren’s syndrome.

RemeGen Co. Ltd., a commercial-stage biotechnology company, recently announced significant progress of Telitacicept, that two Phase III clinical trials in China for the treatment of IgA nephropathy and primary Sjögren’s syndrome have completed patient enrollments.

RemeGen Co. Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a commercial-stage biotechnology company, has recently confirmed that under the 2023 simple renewal mechanism of China National Healthcare Security Administration (NHSA), on January 1, 2024, the updated National Reimbursement Drug List (NRDL) will continue to include Telitacicept (RC18) and Disitamab Vedotin (RC48) for the next two-year agreement.

RemeGen Co. Ltd. recently gave an oral presentation on an interim analysis of the evaluation of the Company’s proprietary Disitamab Vedotin, an investigational anti-HER2 antibody-drug conjugate targeting prevalent solid tumor cancers with significant unmet medical needs, at the European Congress on Gynaecological Oncology held in Barcelona from March 7-10, 2024.

RemeGen Co. Ltd., a commercial-stage biotechnology company, with a mission that is closely aligned with the Close the Care Gap theme of World Cancer Day 2024 which falls on February 4, has announced three major developments that will further the global fight against cancer and forge new paths in tumor treatments.

RemeGen Co. Ltd. announced recently that its independently developed mesothelin -targeting antibody-drug conjugate, RC88, has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.

RemeGen Co. Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a commercial-stage biotechnology company, today announced its two Phase II, open-label, multicenter, single-arm studies for Disitamab Vedotin (RC48-C005 and RC48-C009) have demonstrated consistent efficacy in patients with HER2-positive (immunohistochemistry 3+ or 2+) locally advanced or metastatic urothelial carcinoma (mUC) who have progressed through at least one previous line of systemic chemotherapy.